Search

Your search keyword '"Andresen, S."' showing total 600 results
Start Over Author "Andresen, S."

Refine your results

more »

more »

more »

more »

more »
600 results on '"Andresen, S."'

102. Multiple Unit Umbilical Cord Blood Transplantation (MU UCBT) With Total Body Irradiation, Etoposide And Antithymocyte Globulin For Adult Hematologic Malignancy Patients

Author

Sobecks, R., primary, Copelan, E., additional, Kalaycio, M., additional, Askar, M., additional, Rybicki, L., additional, Serafino, S., additional, Serafin, M., additional, Macklis, R., additional, Dean, R., additional, Pohlman, B., additional, Andresen, S., additional, and Bolwell, B., additional

Published
2010
Full Text
View/download PDF

106. Platelet Engraftment in AML Patients Receiving Matched Related Donor (MRD) Allogeneic Bone Marrow Transplant (alloBMT) Correlates with Major Histocompatibility Complex Class I-Related Molecule A (MICA) Gene Polymorphisms

Author

Sobecks, R.M., primary, Askar, M., additional, Zhang, A., additional, Thomas, D., additional, Kawczak, P., additional, Pidwell, D., additional, Rybicki, L., additional, Jasek, M., additional, Kalaycio, M., additional, Andresen, S., additional, Pohlman, B., additional, Dean, R., additional, Copelan, E., additional, Maciejewski, J., additional, and Bolwell, B., additional

Published
2009
Full Text
View/download PDF

117. 60: A high lactate dehydrogenase (LDH) level predicts for shorter survival following HLA-matched sibling bone marrow transplant (BMT) for patients with acute myelogenous leukemia (AML)

Author

Kalaycio, M., primary, Rybicki, L., additional, Pohlman, B., additional, Dean, R., additional, Sweetenham, J., additional, Andresen, S., additional, Sobecks, R., additional, Sekeres, M., additional, Advani, A., additional, Brown, S., additional, and Bolwell, B., additional

Published
2007
Full Text
View/download PDF

122. Full Dose Vincristine (V) Negatively Impacts Progression Free Survival in Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients Treated with Pegylated Doxorubicin, Vincristine, Reduced-Dose Dexamethasone, and Thalidomide (DVd-T).

Author

Suppiah, R., primary, Walker, E., primary, Almhanna, K., primary, Andresen, S., primary, Reed, J., primary, Karam, M., primary, Phillips, B., primary, Kelly, M., primary, Ellis, E., primary, McGowan, B., primary, and Hussein, M., primary

Published
2005
Full Text
View/download PDF

129. VISCOELASTIC LIMIT OF POLYMER OPTICAL FIBERS: CHARACTERIZATION OF THE DYNAMIC RESPONSE.

Author

Stefani, A., Yuan, W., Andresen, S., and Bang, O.

Subjects
PLASTIC optical fibers, VISCOELASTICITY, MICROSTRUCTURE, SILICA fibers, MODULUS counters, BRAGG gratings
Abstract

Characterization of polymer optical fibers (POFs) in terms of dynamic behavior is important for many sensors applications for which this type of fibers offers big advantages. We report measurements of the Young's modulus on microstructured and step index polymer optical fibers and their comparison with silica fiber for a frequency range up to 300 Hz. In this range a constant modulus has been measured, allowing the use of polymer fibers for applications like Bragg grating based accelerometers. [ABSTRACT FROM AUTHOR]

Published
2011

139. A RANDOMIZED CONTROLLED TRIAL OF SHORT- VERSUS LONG-COURSE VANCOMYCIN AS A COMPONENT OF AN ANTIBIOTIC REGIMEN FOR FEBRILE NEUTROPENIC AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL (PBPC) TRANSPLANT RECIPIENTS.

Author

Avery, R. K., primary, Pohlman, B., additional, Bolwell, B., additional, Tso, E., additional, Goormastic, M., additional, Adal, K. A., additional, Mendez, Z., additional, Goldman, M., additional, Mossad, S. B., additional, Kalaycio, M., additional, Capozzi, D., additional, Schmitt, S. K., additional, Andresen, S., additional, and Longworth, D. L., additional

Published
2000
Full Text
View/download PDF

147. Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS.

Author

Sobecks, R M, Rybicki, L, Yurch, M, Kalaycio, M, Dean, R, Andresen, S, Pohlman, B, Duong, H, Bolwell, B, and Copelan, E

Subjects
INTRAVENOUS therapy, ORAL drug administration, HEMATOPOIETIC stem cell transplantation, PROGENITOR cells, MYELODYSPLASTIC syndromes, ACUTE myeloid leukemia, HEALTH outcome assessment
Abstract

BU and CY is a common conditioning regimen for allogeneic hematopoietic progenitor cell transplantation (HPCT). I.v. BU is increasingly used in place of the oral formulation for conditioning. We compared the outcomes of 135 consecutively treated AML and myelodysplastic syndrome patients who underwent allogeneic HPCT at our institution with BUCY2 using oral (n=93) or i.v. (n=42) BU, without dose adjustment. The i.v. BU patients had a lower incidence of any severity of oral mucositis (3 versus 55%, P=0.002) and severe mucositis (3 versus 24%, P=0.005). Other post transplant outcomes were comparable between the groups. In all 26 i.v. BU and 33 oral BU patients are alive; however, the median follow-up was significantly longer for the oral BU group. One- and two-year non-relapse mortality for the i.v. BU patients was 21% for both, and for the oral BU group was 23% and 29%, respectively. One- and two-year relapse mortality for the i.v. BU patients was 21% for both, and for the oral BU group was 24% and 29%, respectively. Substituting i.v. for oral BU reduces variability in drug exposure and potentially improves toxicity as suggested by our finding of significantly less oral mucositis and decreased severity with i.v. BU. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

148. Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation.

Author

Waterman, J, Rybicki, L, Bolwell, B, Copelan, E, Pohlman, B, Sweetenham, J, Dean, R, Sobecks, R, Andresen, S, and Kalaycio, M

Subjects
FLUDARABINE, LYMPHOMAS, MYELODYSPLASTIC syndromes, HEMATOPOIETIC stem cell transplantation, MITOXANTRONE, DRUG therapy
Abstract

Fludarabine is an effective treatment for follicular lymphoma (FL), but exposure to it negatively impacts stem cell mobilization and may increase the risk of subsequent myelodysplastic syndrome and acute myelogenous leukemia (t-MDS/AML). We hypothesized that the risk that fludarabine imparts to stem cell mobilization and t-MDS/AML would be affected by dose or timing. All patients with FL treated at Cleveland Clinic from 1991 to 2007 with autologous hematopoietic cell transplantation were evaluated. Recursive partitioning analysis was used to explore associations of fludarabine and mitoxantrone dose and timing with poor stem cell harvest and t-MDS/AML. We identified 171 patients, of whom 52 previously received fludarabine. Patients exposed to fludarabine prior to auto-HCT were more likely to require >5 days of leukapheresis (P<0.001) and second stem cell mobilization (P<0.001), especially at a cumulative dose >150 mg/m2. Univariable risk factors for t-MDS/AML included the number of chemotherapy regimens before auto-HCT, the need for >5 days of leukapheresis to collect CD34+ cells and fludarabine exposure in a dose-dependent manner, particularly when >500 mg/m2. A cumulative dose of fludarabine >150 mg/m2 increases the risk for poor stem cell harvests and any exposure increases the risk of t-MDS/AML, with the greatest risk being at doses >500 mg/m2. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

149. Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia.

Author

Mahindra, A, Bolwell, B J, Rybicki, L, Elder, P, Kalaycio, M, Dean, R, Avalos, B, Sobecks, R, Tench, S, Andresen, S, Pohlman, B, Sweetenham, J, Devine, S, and Copelan, E

Subjects
ETOPOSIDE, LYMPHOMAS, STEM cells, AUTOTRANSPLANTATION, HODGKIN'S disease
Abstract

The use of etoposide (VP-16) for stem cell mobilization has been reported as a significant risk factor for the development of therapy-related myelodysplasia/therapy-related AML (tMDS/tAML) after transplantation. We compared the safety and effectiveness of VP-16+G-CSF (VP+G) to G-CSF alone for PBPC mobilization in patients with non-Hodgkin's lymphoma and Hodgkin's lymphoma who underwent autologous transplantation at the Cleveland Clinic and Ohio State University. In the VP+G group, median total CD34+ cells collected were 9.34 × 106 per kg (range 0.97-180.89), with 42% of all patients having adequate (2 × 106 cells per kg) CD 34+ collection after 2 days of apheresis compared with a median in the G-CSF group of 3.83 × 106 per kg (range, 0.72-50.38), with only 16% patients having adequate collection after 2 days (P<0.001). tMDS/tAML occurred in 15 patients (2.3%) in the VP+G and in 12 patients (3.8%) receiving G-CSF alone. (P=0.62). Increased number of days of apheresis was associated with the risk of tMDS/tAML (hazard ratio (HR) 1.19, 95% confidence interval (CI) 1.08-1.30, P<0.001). Priming regimen was not a significant variable for relapse-free survival or OS. The addition of etoposide significantly improves the effectiveness of mobilization at the cost of an increased incidence of neutropenic fever though with no mortalities. There is no evidence of increased incidence of tMDS/tAML in patients receiving VP+G compared with those mobilized with G-CSF alone. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

150. Apheresis days required for harvesting CD34+ cells predicts hematopoietic recovery and survival following autologous transplantation.

Author

Malik, S, Bolwell, B, Rybicki, L, Copelan, O, Duong, H, Dean, R, Sobecks, R, Kalaycio, M, Sweetenham, J, Pohlman, B, Andresen, S, Tench, S, Koo, A, Figueroa, P, and Copelan, E

Subjects
AUTOTRANSPLANTATION, ETOPOSIDE, BLOOD platelets, MULTIVARIATE analysis, HEMATOPOIETIC stem cells, NEUTROPHILS
Abstract

We sought to determine whether patients requiring more aphereses to obtain adequate numbers of CD34+ cells had delayed hematopoietic recovery following autologous transplantation. We identified 496 consecutive individuals with lymphoma who underwent hematopoietic stem cell mobilization using etoposide and G-CSF and first autologous transplantation. In multivariate analysis, increased apheresis days as a continuous and as a categorical variable at 5/<5 days significantly predicted neutrophil recovery. Apheresis days fell just short of significance (P=0.06) as a predictor of platelet recovery in multivariate analysis. Increased apheresis days (as both continuous and categorical variables) were also predictive of treatment-related myelodysplastic syndrome/AML. Patients who underwent 5 days of pheresis had significantly worse survival (P=0.001) than patients with less pheresis days owing to significantly higher relapse mortality (P=0.001). [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results